Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Election of Two Class I Directors





On November 18, 2020, Actinium Pharmaceuticals, Inc. (the "Company") held its
2020 annual meeting of stockholders (the "Annual Meeting"). As previously
reported in the Company's definitive proxy statement filed with the Securities
and Exchange Commission on October 7, 2020 (the "2020 Proxy"), the terms of the
Company's two Class I directors were scheduled to expire at the Annual Meeting,
and the Company's board of directors (the "Board") nominated each of them for
re-election at the Annual Meeting.



At the Annual Meeting, David Nicholson and Richard I. Steinhart were elected as
Class I directors of the Board to serve for a term expiring at the Company's
2023 annual meeting of stockholders.

Amendment to the Actinium Pharmaceutical, Inc. 2019 Plan





At the Annual Meeting, the stockholders approved the Amendment (the "Amendment")
to the Actinium Pharmaceuticals, Inc. 2019 Plan (the "2019 Plan") to increase
the number of shares of common stock available for issuance pursuant to awards
under the 2019 Plan by an additional 2,750,000 shares, to a total of 3,083,333
shares of the Company's common stock.



For more information about the matters above, see the Company's 2020 Proxy, the
relevant portions of which are incorporated herein by reference. The description
of the 2019 Plan and the Amendment above and such portions of the 2020 Proxy are
qualified in their entirety by reference to the full text of the 2019 Plan, as
implemented by the Board and previously approved by the stockholders on December
18, 2019, and the Amendment, filed as Exhibits 10.1 and 10.2, respectively, to
this Current Report on Form 8-K and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.



A total of 9,467,356 shares of the Company's common stock were present in person
or represented by proxy at the Annual Meeting. Holders of the Company's common
stock were entitled to one vote per share. At the Company's Annual Meeting, the
following three proposals were submitted to the Company's stockholders:

(1) Election of two directors to serve as Class I directors on the Company's

Board of Directors to serve until our 2023 Annual Meeting of Stockholders or


     until successors have been duly elected and qualified or until their earlier
     resignation or removal:




                                                                                                         Broker
Director                                       For           Against        Withheld /Abstained        Non-Votes
David Nicholson                              3,384,556          0                 872,844              5,209,956
Richard I. Steinhart                         3,563,430          0                 693,970              5,209,956

(2) Approval of an amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan to

increase the total number of shares of common stock authorized for issuance


     under such plan from 333,333 by 2,750,000 to a total of 3,083,333 shares:


    For           Against        Withheld /Abstained       Broker Non-Votes
  2,731,692       1,318,190              207,518                5,209,956

(3) Ratification of the appointment of Marcum LLP as the Company's independent


     registered public accounting firm for the 2020 fiscal year:


    For          Against       Withheld /Abstained      Broker Non-Votes
  8,996,462       295,540              175,354                      0

For more information about the foregoing proposals, see the Company's 2020 Proxy, the relevant portions of which are incorporated herein by reference.

The results reported above are final voting results. No other matters were considered or voted upon at the meeting.



                                       1

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit Number                            Description
10.1               Actinium Pharmaceuticals, Inc. 2019 Plan
10.2               Amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan




                                       2

© Edgar Online, source Glimpses